Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Article
Synta stops melanoma drug trials due to serious safety risks
National report - Synta Pharmaceuticals has stopped drug trials for a melanoma drug due to serious safety issues, Forbes.com reports.
National report
- Synta Pharmaceuticals has stopped drug trials for a melanoma drug due to serious safety issues, Forbes.com reports.
The drug, called elesclomol, was supposed to work by increasing oxidative stress, which would cause cancer cells to self-destruct. However, during the trials there was a higher death rate among patients taking the experimental drug, according to Forbes.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Related Videos
Related Content
